Alnylam set for further expansion in ‘gene silencing’ but Dicerna could have best-in-class rival.
Drugs in the RNA interference (RNAi) class will truly become a force to be reckoned with in 2020, but trailblazer Alnylam Pharmaceuticals Inc. will also see its lead challenged by rivals.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.
Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.
BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.
Start-ups from China dominated the fastest-growing share prices for mid-cap biopharma companies in Q1, while the biggest decliners were mainly US firms.
The agency loosened requirements for echocardiograms and removed contraindications for a number of commonly used drugs.
The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.
Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.
